KDIGO 53-58

A detailed and informative graphic illustrating the relationship between chronic kidney disease and diabetes, featuring visual elements such as kidney icons, glucose control mechanisms, and pharma options like SGLT2 inhibitors, and GLP-1 receptor agonists, with a professional medical aesthetic.

KDIGO Renal & Diabetes Quiz

Test your knowledge on the management of patients with chronic kidney disease (CKD) and diabetes. This quiz covers essential aspects of pharmacotherapy and clinical guidelines related to kidney function and glucose control.

5 multiple-choice questions
Focus on real-world clinical applications
Improve your understanding of CKD and diabetes management

5 Questions1 MinutesCreated by DiagnosingDoctor28

In UKPDS metformin: (alegeti afirmatia falsa)

Cei pe metformin nu au avut crestere in greutate sau au avut dar foarte putin

Scade Hba1c similar cu insulina

Scade HbA1c mai mult decat insulina

Scade HbA1c mai mult decat iDDP4

Cum abordam un pacient cu BRC insa nou diagnosticat cu DZ si cu eRFG peste 30?

Initiem iSGLT2 in prima faza apoi metformin pentru o scadere cat mai rapida a riscului de progresie al bolii renale

Prima linie de tratament: metformin

Daca are IMC peste 30, prima linie de tratament GLP1-RA apoi iSGLT2 apoi metformin

Incepem cu doza maxima tolerata de metformin si de iSGT2

Daca avem un pacient cu BRC si albuminurie, care dintre cele doua iSGLT2 preferam. Alegeti varianta cu iSGLT2 care are mai multe sageti in jos la albuminurie (din studii- EMPA REG OUTCOME si DECLARE TIMI 58)

Empaglifozin

Dapaglifozin

Care este medicamentul mai putin potrivit la un pacient cu BRC si risc cardio-vascular inalt si foarte inalt

TZD

ISGLT2

GLP1RA

Metformin

KDIGO 53-58

KDIGO Renal & Diabetes Quiz

More Surveys